Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chronic Obstructive Pulmonary Disorder: later-stage trial registry
1 of 2 indexed Chronic Obstructive Pulmonary Disorder trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Chronic Obstructive Pulmonary Disorder: 2 US clinical trials tracked, 1 recruiting.
Chronic Obstructive Pulmonary Disorder is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Pearl Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition chronic-obstructive-pulmonary-disorder
OPEN 1 | RECR 50% | LATE 1 | EARLY 0 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Chronic Obstructive Pulmonary Disorder lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chronic Obstructive Pulmonary Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chronic Obstructive Pulmonary Disorder is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
COPD Patient-Powered Research Network
COPD Foundation
NCT02803242
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
Pearl Therapeutics
NCT02766608
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Chronic Obstructive Pulmonary Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chronic Obstructive Pulmonary Disorder trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chronic Obstructive Pulmonary Disorder page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Chronic Obstructive Pulmonary Disorder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pearl Therapeutics sponsors the most Chronic Obstructive Pulmonary Disorder trials on record, review their full trial history before evaluating a specific study. See Pearl Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Obstructive Pulmonary Disorder condition card totals 2 registered trials; most-linked intervention Symbicort® TBH 400/12 μg BID; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.